Skip to main content
Molecular Therapy. Methods & Clinical Development logoLink to Molecular Therapy. Methods & Clinical Development
. 2022 Dec 8;28:11. doi: 10.1016/j.omtm.2022.11.008

Self-amplifying mRNA bicistronic influenza vaccines raise cross-reactive immune responses in mice and prevent infection in ferrets

Cheng Chang, Nedzad Music, Michael Cheung, Evan Rossignol, Sukhmani Bedi, Harsh Patel, Mohammad Safari, Changkeun Lee, Gillis R Otten, Ethan C Settembre, Giuseppe Palladino, Yingxia Wen
PMCID: PMC9747525  PMID: 36570424

Main text

(Molecular Therapy: Methods & Clinical Development 27, 195–205; December 2022)

In the originally published version of this article, the vaccine doses were written incorrectly in the sections titled “sa-mRNA bicistronic A/H5N1 vaccines induced potent H5 and N1 neutralizing antibody titers in mice.” and “sa-mRNA bicistronic A/H3N2 and B/Yamagata vaccines induced potent neutralizing antibody responses and cellular immune responses in mice.” The doses were written as 1.0 μg RNA or 0.1 μg RNA when they should be 1.0 μg or 0.01 μg throughout the results section.

These changes have been reflected online, and the authors apologize for this error.


Articles from Molecular Therapy. Methods & Clinical Development are provided here courtesy of American Society of Gene & Cell Therapy

RESOURCES